Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma

7 Apr 2021

Abstract excerpt

Ovarian clear cell carcinoma (OCCC) is a histological subtype of ovarian cancer that is more frequent in Asian countries (~25% of ovarian cancers) than in US/European countries (less than 10%). OCCC is refractory to conventional platinum-based chemotherapy, which is effective against high-grade serous carcinoma (HGSC), a major histological subtype of ovarian cancer. Notably, deleterious mutations in SWI/SNF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33917230
DOI: 10.3390/cancers13081769

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaPMID 33917230Read ↗

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read ↗

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategiesSemantic proximity Read ↗

Precision medicine for ovarian clear cell carcinoma based on gene alterations.Semantic proximity Read ↗

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Targeting DNA Damage Response Pathway in Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant SubtypesSemantic proximity Read ↗

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature ReviewSemantic proximity Read ↗

Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.Semantic proximity Read ↗

SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.